The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to investigators at St. Jude Children’s Research Hospital.

The researchers showed that mesenchymal cells in the bone marrow create a protective niche for leukemic cells by releasing large amounts of asparagine, an amino acid that nearby leukemic cells must have to survive but do not make efficiently. This extra supply of asparagine helps leukemic cells survive treatment with asparaginase, a drug that normally would deplete their supply of this vital nutrient.

“This insight from this study will help researchers to find ways to disrupt this safe haven for leukemic cells that need asparagine,” added James R. Downing, M.D., St. Jude scientific director and chair of the Pathology department. Downing is a co-author of paper.

The study’s findings also suggest that drugs now being developed to block the enzyme that makes asparagine should be tested to see if they also prevent mesenchymal cells from making this amino acid. In addition, the ability of mesenchymal cells to make asparagine might be decreased by cancer drugs that are already known to disrupt the activity of those cells.

The experiments for this study were performed primarily by Shotaro Iwamoto, M.D., first author of the paper, and Keichiro Mihara, a co-author, postdoctoral fellows in Campana’s laboratory.

This work was supported in part by the National Cancer Institute and ALSAC.

St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.

Related Health News:

1. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations ATIR(TM) Data Presented at the Annual EBMT Presidential Symposium AMSTERDAM, April 8/PRNewswire/ — Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its...
2. Marker for Colon Stem Cells Discovered Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of...
3. Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth BRISBANE, Australia, April 20 /PRNewswire-FirstCall/ — Progen Pharmaceuticals Limited (NASDAQ:PGLA) has released data that shows its epigenetic technology successfully inhibits tumor growth. The results of...
4. Risky Department of Health Scheme Failing People With MS In 2002 the National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of Multiple Sclerosis were not cost effective. In...
5. First US Patient Randomized in ALSYMPCA Phase III Study Algeta ASA (OSE: ALGETA), the cancer therapeutics company, has recently announced that the first clinical center in the US, the Tulane Cancer Center, New Orleans,...